Purple Biotech (NASDAQ:PPBT) Shares Cross Above 50 Day Moving Average – Time to Sell?

Purple Biotech Ltd. Sponsored ADR (NASDAQ:PPBT) passed above its 50 day moving average during trading on Wednesday. The stock has a 50 day moving average of $1.41 and traded as high as $1.49. Purple Biotech shares last traded at $1.49, with a volume of 20,258 shares.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded Purple Biotech from a “sell (e+)” rating to a “sell (e)” rating in a report on Thursday, October 29th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $30.00.

Purple Biotech Stock Up 11.2%

The business has a fifty day moving average of $1.41 and a 200 day moving average of $2.84. The company has a market cap of $1.38 million, a P/E ratio of -0.06 and a beta of 0.77.

About Purple Biotech

Purple Biotech Ltd. (NASDAQ:PPBT) is a clinical-stage biopharmaceutical company focused on developing therapies for cancer. The company’s research programs are designed to address mechanisms that contribute to tumor growth, immune evasion and resistance to existing treatments. Purple Biotech’s pipeline has included CM24, a humanized monoclonal antibody targeting CEACAM1, an immune checkpoint involved in tumor-immune interactions. The company has evaluated CM24 in combination with other cancer therapies, including immune checkpoint inhibitors, for advanced solid tumors such as metastatic pancreatic cancer.